Mauna Kea Technologies Aktie

Mauna Kea Technologies SA engages in the design, development, and sale of optical biopsy devices and tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts primarily in cancer patients. Its product, Cellvizio, a probe-based Confocal Laser Endomicroscopy system, provides physicians and researchers high resolution cellular views of tissue inside the body. Mauna Kea Technologies was founded by Sacha Loiseau and Benjamin Abrat in May 2000 and is headquartered in Paris, France.